Imatinib reduces proliferation of leukemic cells in vitro

Authors

  • Naif Abdulla Alanazi Dept. of Surgery, Prince Mohamed bin Abdulaziz Hospital, Riyadh
  • Naif Enad Alanazi Dept. of Medicine, King Salman Hospital, Riyadh
  • Faisal Farhan J Alanazi Riyadh College for Dentistry, Riyadh, Saudi Arabia
  • Saud Altamimi Dept. of Med Lab Sci., CAMS, Prince Sattam bin Abdulaziz University, Al-Kharj
  • Osama S Alghamdi Dept. of Med Lab Sci., CAMS, Prince Sattam bin Abdulaziz University, Al-Kharj
  • Abdulrahman Alanazi Dept. of Med Lab Sci., CAMS, Prince Sattam bin Abdulaziz University, Al-Kharj
  • Mohamed Al Shahrani Dept. of Med Lab Sci., CAMS, Prince Sattam bin Abdulaziz University, Al-Kharj
  • Mohamed W Al Rabea College of Medicine, King Abdulaziz University, Jeddah
  • Arfan Arshad Dar Shefa Hospital, Riyadh
  • Faris Q Alenzi Dar Shefa Hospital, Riyadh, Saudi Arabia, Dept. of Med Lab Sci., CAMS, Prince Sattam bin Abdulaziz University, Al-Kharj

DOI:

https://doi.org/10.3329/bjms.v16i2.31945

Abstract

Introduction: Philadelphia chromosome is a cytogenetic marker for chronic myeloid leukemia (CML). The main aims of this study were to assess the positive responses, side-effects and survival of CML patients treated with imatinib mesylate.

Methods: All recently diagnosed CML patients who were treated with imatinib were recruited to this study. We investigated hematological and cytogenetic parameters by CBC, FISH and RT-PCR individually.

Results: Of the 10 cases, 7 (70%) were males and 3 (30%) were female. Four (40%) of the cases were analyzed retrospectively and 8 cases (80%) exhibited general exhaustion (75%), fever (80%), and splenomegaly (80%). Indications of bleeding and rashes were rarely seen at presentation. The majority of the patients had a generally low risk profile (70%), 30% had intermediate risk; with no subjects exhibiting high risk CML, 9 subjects (90%) were in remission. One patient (10%) had been in remission for 3 years, 4 (40%) had been in remission for 6 years, one was in remission after 7 years and 5 (50%) were in remission after 10 years. Most of the patients (90%) exhibited a deficient major molecular reaction, after 6 years of treatment and 42% of them had a deficient major molecular reaction after 10 years of treatment. No significant side effects associated with Imatinib treatment were reported by the patients. Imatinib treatment resulted in diminished expansion in CML CFU-GM cells.

Conclusion: Imatinib mesylate is indicated for the treatment of Philadelphia chromosome-positive CP-CML with no significant adverse outcomes.

Bangladesh Journal of Medical Science Vol.16(2) 2017 p.320-324

Downloads

Download data is not yet available.
Abstract
1172
PDF
925

Author Biography

Naif Abdulla Alanazi, Dept. of Surgery, Prince Mohamed bin Abdulaziz Hospital, Riyadh



Downloads

Published

2017-03-23

How to Cite

Alanazi, N. A., Alanazi, N. E., Alanazi, F. F. J., Altamimi, S., Alghamdi, O. S., Alanazi, A., Shahrani, M. A., Rabea, M. W. A., Arshad, A., & Alenzi, F. Q. (2017). Imatinib reduces proliferation of leukemic cells in vitro. Bangladesh Journal of Medical Science, 16(2), 320–324. https://doi.org/10.3329/bjms.v16i2.31945

Issue

Section

Original Articles